UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.29 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,236 shares of the company's stock after purchasing an additional 6,422 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.07% of MoonLake Immunotherapeutics worth $2,287,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Woodline Partners LP increased its stake in shares of MoonLake Immunotherapeutics by 26.3% during the fourth quarter. Woodline Partners LP now owns 293,535 shares of the company's stock worth $15,895,000 after purchasing an additional 61,105 shares during the period. Wexford Capital LP increased its stake in shares of MoonLake Immunotherapeutics by 71.4% during the fourth quarter. Wexford Capital LP now owns 24,000 shares of the company's stock worth $1,300,000 after purchasing an additional 10,000 shares during the period. Point72 Asset Management L.P. bought a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth approximately $5,346,000. Polar Capital Holdings Plc increased its stake in shares of MoonLake Immunotherapeutics by 120.0% during the fourth quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company's stock worth $59,565,000 after purchasing an additional 600,000 shares during the period. Finally, Paradigm Biocapital Advisors LP increased its stake in shares of MoonLake Immunotherapeutics by 90.3% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock worth $95,965,000 after purchasing an additional 840,731 shares during the period. Institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Down 4.0%

Shares of MLTX traded down $1.95 during midday trading on Friday, hitting $46.88. The company's stock had a trading volume of 881,415 shares, compared to its average volume of 377,607. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26. The company's fifty day simple moving average is $39.15 and its two-hundred day simple moving average is $43.91. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -36.34 and a beta of 1.23.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period in the prior year, the business posted ($0.22) earnings per share. On average, research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Analyst Ratings Changes

MLTX has been the topic of a number of recent research reports. Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price objective on the stock in a research note on Monday, May 19th. The Goldman Sachs Group lowered their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Wedbush restated an "outperform" rating and set a $80.00 price objective (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $67.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $78.71.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.